• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe colitis complicating secukinumab (Cosentyx ) therapy.

作者信息

Lee A S W, Levell N J, Shah S N, Gaffney K, Tremelling M A W

机构信息

Department of Dermatology, Norfolk and Norwich University Hospital, Colney Lane, Norwich, NR4 7UY, UK.

Department of Rheumatology, Norfolk and Norwich University Hospital, Colney Lane, Norwich, NR4 7UY, UK.

出版信息

Clin Exp Dermatol. 2020 Apr;45(3):344-345. doi: 10.1111/ced.14149. Epub 2019 Dec 19.

DOI:10.1111/ced.14149
PMID:31854471
Abstract
摘要

相似文献

1
Severe colitis complicating secukinumab (Cosentyx ) therapy.司库奇尤单抗（可善挺）治疗引发的严重结肠炎。
Clin Exp Dermatol. 2020 Apr;45(3):344-345. doi: 10.1111/ced.14149. Epub 2019 Dec 19.
2
Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis.使用司库奇尤单抗治疗银屑病期间出现的矛盾性溃疡性结肠炎。
Eur J Dermatol. 2019 Aug 1;29(4):444-445. doi: 10.1684/ejd.2018.3391.
3
Clinical outcomes in patients on secukinumab (Cosentyx ) within a specialist psoriasis clinic: a single centre, retrospective cohort study.在一家专科银屑病诊所中使用司库奇尤单抗（可善挺）治疗的患者的临床结局：一项单中心回顾性队列研究。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e89-e91. doi: 10.1111/jdv.15245. Epub 2018 Oct 1.
4
Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report.司库奇尤单抗治疗合并多发性硬化症的斑块状银屑病患者：一篇包含典型病例报告的小型综述
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e110-e112. doi: 10.1111/jdv.16035. Epub 2019 Nov 14.
5
Secukinumab-induced ulcerative colitis: opening Pandora's box of immunity.司库奇尤单抗诱发的溃疡性结肠炎：打开免疫的潘多拉魔盒。
Gastroenterol Hepatol. 2020 Aug-Sep;43(7):358-359. doi: 10.1016/j.gastrohep.2019.12.004. Epub 2020 Jun 17.
6
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.一项评估司库奇尤单抗在 158 例患者真实环境中的有效性和安全性的前瞻性多中心研究。
J Am Acad Dermatol. 2019 Aug;81(2):427-432. doi: 10.1016/j.jaad.2019.02.062. Epub 2019 Mar 11.
7
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.司库奇尤单抗在治疗中度至重度银屑病患者中，通过两年治疗展现出持续清除皮肤症状及改善患者报告结局的疗效：CLEAR研究结果
J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6.
8
Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.银屑病患者长期使用司库奇尤单抗的延续性：与患者特征和初始银屑病清除的关联。
Clin Exp Dermatol. 2019 Oct;44(7):e230-e234. doi: 10.1111/ced.13999. Epub 2019 May 22.
9
Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.阿普米拉斯与司库奇尤单抗联合治疗中重度、顽固性斑块状银屑病患者。
Clin Exp Dermatol. 2019 Oct;44(7):e243-e244. doi: 10.1111/ced.14000. Epub 2019 May 20.
10
IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.白细胞介素 17A 抑制剂转换 - 司库奇尤单抗治疗失败后使用依奇珠单抗的疗效。一项单中心经验。
Acta Derm Venereol. 2019 Jul 1;99(9):769-773. doi: 10.2340/00015555-3200.

引用本文的文献

1
IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis.白细胞介素-17抑制剂相关的炎症性肠病：一项基于文献和数据库分析的研究
Front Pharmacol. 2023 Mar 23;14:1124628. doi: 10.3389/fphar.2023.1124628. eCollection 2023.
2
Colonic Dilatation Complicating Acute Severe Ulcerative Colitis Managed Successfully with Accelerated Infliximab Dosing.结肠扩张并发急性重症溃疡性结肠炎，通过加速英夫利昔单抗给药成功治疗
Case Rep Gastroenterol. 2023 Feb 7;17(1):82-88. doi: 10.1159/000529152. eCollection 2023 Jan-Dec.
3
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.
白细胞介素-17A抑制剂司库奇尤单抗的安全性综述
Pharmaceuticals (Basel). 2022 Nov 7;15(11):1365. doi: 10.3390/ph15111365.
4
Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?银屑病治疗是否会增加炎症性肠病的风险？
Pharmaceut Med. 2020 Aug;34(4):257-262. doi: 10.1007/s40290-020-00340-1.